For patients living with MOGAD — a rare autoimmune condition in which the body turns against the protective sheath of its own nerve fibers — the absence of approved preventive treatments has long meant navigating repeated crises without a reliable map. A Mayo Clinic-led study, drawing on 116 patients across the Americas and published in JAMA Neurology, now offers something rare in this space: real-world evidence that IL-6 receptor blockers tocilizumab and satralizumab can meaningfully reduce the frequency of these debilitating attacks. In a disease too uncommon for any single institution to st
IL-6 Receptor Blockers Show Promise in Preventing MOGAD Relapses
MOGAD patients experience vision loss, paralysis, and accumulating neurological disability from repeated inflammatory attacks without approved preventive treatments.